- Report
- November 2025
- 150 Pages
Global
From €5405EUR$5,950USD£4,666GBP
- Report
- June 2026
- 181 Pages
Global
From €3220EUR$3,545USD£2,780GBP
€3578EUR$3,939USD£3,089GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,521GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,521GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,521GBP
- Report
- June 2026
- 384 Pages
Global
From €5314EUR$5,850USD£4,588GBP
- Report
- August 2025
- 188 Pages
Global
From €4088EUR$4,500USD£3,529GBP
- Report
- November 2025
- 200 Pages
Global
From €7222EUR$7,950USD£6,235GBP
- Report
- March 2026
- 148 Pages
Global
From €3633EUR$3,999USD£3,136GBP
- Report
- September 2025
- 271 Pages
Global
From €4538EUR$4,995USD£3,917GBP
- Report
- February 2026
- 188 Pages
Global
From €4406EUR$4,850USD£3,804GBP
- Report
- September 2025
- 124 Pages
Global
From €3500EUR$4,127USD£3,127GBP
- Report
- October 2025
- 160 Pages
Global
From €4406EUR$4,850USD£3,804GBP
- Report
- May 2023
- 190 Pages
Global
From €2226EUR$2,450USD£1,921GBP
- Report
- January 2019
- 144 Pages
Global
From €2498EUR$2,750USD£2,157GBP
- Report
- September 2024
- 82 Pages
Japan
From €3179EUR$3,500USD£2,745GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1817EUR$2,000USD£1,568GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €2271EUR$2,500USD£1,961GBP
- Clinical Trials
- April 2025
- 240 Pages
Global
From €2271EUR$2,500USD£1,961GBP
- Report
- March 2022
- 146 Pages
Global
From €6813EUR$7,500USD£5,882GBP

The Endothelin Receptor Antagonist (ERA) market is a subset of the cardiovascular drug market. ERA drugs are used to treat a variety of cardiovascular conditions, including hypertension, pulmonary arterial hypertension, and congestive heart failure. These drugs work by blocking the action of endothelin, a hormone that can cause constriction of the blood vessels. This helps to reduce blood pressure and improve blood flow. ERA drugs are generally well-tolerated and have few side effects.
The ERA market is highly competitive, with several major pharmaceutical companies offering products. These include Amgen, Bayer, Merck, Novartis, and Pfizer. Other companies, such as Actelion, Gilead, and United Therapeutics, also offer ERA drugs. These companies are continually researching and developing new drugs to improve the treatment of cardiovascular conditions. Show Less Read more